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Abstract: Objective: To investigate the effects of Shenling Baizhu Powder (SLBZP) on expression of apoptosis related 
proteins such as Caspase-3, Caspase-9, X-linked inhibitor of apoptosis (XIAP), PDGF-BB, Ang-1, Ang-2 of tumor chemotherapy 
model mice with H22 hepatocellular carcinoma cells. Methods: Sixty-four Kunming mice were subcutaneously injected with 
suspension of H22 hepatocellular carcinoma cells (2×107/mL) into the right anterior armpit. After 1 week, all transplanted tumors 
were formed and the mice were received intraperitoneal injection with cytoxan (CTX) with the dosage of 0.2g/kg to establish the 
tumor chemotherapy model. Then mice were randomly divided into eight groups. CTX group was treated with CTX (0.02g/kg), 
the model group was treated with physiologic saline, three SLBZP groups were treated with SLBZP (6.00, 3.00, 1.50g/kg), and 
other three groups were treated with SLBZP (6.00, 3.00, 1.50g/kg) plus CTX (0.02g/kg). After all groups were treated for 14 days, 
Western blot was used to detect the expression of Caspase-3, Caspase-9 and XIAP proteins in tumor tissue, and protein expression 
of PDGF-BB, Ang-1, Ang-2 in blood was measured by enzyme-linked immunosorbent assay (ELISA). Results: The combined 
treatment group had obvious effect on tumor inhibition. Tumor inhibitory ratios in CTX alone, SLBZP (H), SLBZP (H) plus CTX, 
and SLBZP (M) plus CTX groups were 52.39%, 45.84%, 58.41% and 52.77% respectively. Compared to the model group, the 
protein expressions of PDGF-BB, Ang-1, Ang-2, and XIAP in tumor tissue were obviously lower than those in all treated groups. 
And the expressions of Caspase-3 and Caspase-9 in tumor tissue showed a trend of up-regulation. And the effect in SLBZP (H) 
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plus CTX group was the most significant (P<0.01, P<0.05). Conclusion: SLBZP can more effectively adjust the expression of 
apoptosis related proteins of tumor in mice with H22 hepatocellular carcinoma cells, and promoting tumor apoptosis may be one 
of the possible mechanisms of SLBZP to improve chemotherapy in treating hepatic cancer.
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3. 分组与给药 造模2 4h后将6 4只小鼠，随
机分为模型组，CTX组，SLBZP高、中、低剂量组、
SLBZP高、中、低剂量加CTX组，共8组，每组8只。




























































模型组 6 98.21±33.00 732.23±338.83 -
CTX组 7 47.86±24.50 369.49±153.95 52.39
SLBZP高剂量组 6 59.88±18.65 440.10±240.36 45.84
SLBZP中剂量组 7 64.63±23.85 452.01±279.46 28.25
SLBZP低剂量组 7 85.40±56.88 512.74±246.80 29.88
SLBZP高剂量+CTX组 7 39.38±29.69 223.58±75.97** 58.41
SLBZP中剂量+CTX组 6 45.27±27.47 338.87±166.31* 52.77
SLBZP低剂量+CTX组 6 47.20±21.09 394.47±212.62 37.96
















模型组 6 36.34±9.41 15.13±1.73 81.09±15.97
CTX组 7 26.50±4.90 10.12±4.53 67.91±10.91
SLBZP高剂量组 6 25.00±6.59 8.63±6.15 68.40±17.27
SLBZP中剂量组 7 28.51±3.93 9.53±4.76 77.09±10.17
SLBZP低剂量组 7 31.07±4.86 12.04±8.60 73.45±11.45
SLBZP高剂量+CTX组 7 20.52±5.76** 4.40±2.52** 53.01±12.93*
SLBZP中剂量+CTX组 6 22.08±8.69* 9.25±2.95 58.73±18.35
SLBZP低剂量+CTX组 6 26.07±7.64 9.16±4.35 67.23±19.00


















































































注：1. 模型组；2. CTX组；3. SLBZP高剂量组；4. SLBZP中剂量
组；5. SLBZP低剂量组；6. SLBZP高剂量+CTX组；7. SLBZP中剂量+ 
CTX组；8. SLBZP低剂量+CTX组。
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注：1. 模型组；2. CTX组；3. SLBZP高剂量组；4. SLBZP中剂量
组；5. SLBZP高剂量+CTX组；6. SLBZP中剂量+CTX组。下图同。
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